Metachromatic leukodystrophy: Diagnosis and treatment challenges

Nayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Niño, Juanita Trejos-Suárez, Norma Cecilia Serrano-Diaz

Research output: Articles / NotesArticle in a non-specialized journalpeer-review

1 Scopus citations


Metachromatic leukodystrophy is a neurological disease of the lysosomal deposit that has a significant impact given the implications for the neurodegenerative deterioration of the patient. Currently, there is no treatment available that reverses the development of characteristic neurological and systemic symptoms. Objective. Carry out an updated bibliographic search on the most critical advances in the treatment and diagnosis for LDM. A retrospective topic review published in English and Spanish in the Orphanet and Pubmed databases. Current treatment options, such as enzyme replacement therapy and hematopoietic stem cell transplantation aimed at decreasing the rapid progression of the disease, improving patient survival; however, these are costly. The pathophysiological events of intracellular signaling related to the deficiency of the enzyme Arylsulfatase A and subsequent accumulation of sulphatides and glycosylated ceramides have not yet been established. Recently, the accumulation of C16 sulphatides has been shown to inhibit glycolysis and insulin secretion in pancreatic cells. The significant advance in technology has allowed timely diagnosis in patients suffering from LDM; however, they still do not have an effective treatment.

Original languageEnglish
Pages (from-to)2083-2090
Number of pages8
Issue number3
StatePublished - 2021
Externally publishedYes


  • Diagnosis
  • Metachromatic leukodystrophy
  • Prevalence
  • Treatment


Dive into the research topics of 'Metachromatic leukodystrophy: Diagnosis and treatment challenges'. Together they form a unique fingerprint.

Cite this